210 related articles for article (PubMed ID: 32245484)
1. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
[TBL] [Abstract][Full Text] [Related]
3. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
5. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
[TBL] [Abstract][Full Text] [Related]
6. IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
Yang J; Chen J; Chang J; Sun X; Wei Q; Cai X; Cao P
Cell Commun Signal; 2024 Feb; 22(1):116. PubMed ID: 38347540
[TBL] [Abstract][Full Text] [Related]
7. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract][Full Text] [Related]
8. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
Li Z; Wu X; Jia L; Li J; Zhang R; Tang H; Li Z; Bu H; Shen C
Bioorg Med Chem Lett; 2020 May; 30(9):127070. PubMed ID: 32143887
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
Che J; Huang F; Zhang M; Xu G; Qu B; Gao J; Chen B; Zhang J; Ying H; Hu Y; Hu X; Zhou Y; Gao A; Li J; Dong X
Eur J Med Chem; 2020 Oct; 203():112491. PubMed ID: 32679449
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.
Khalil AF; El-Moselhy TF; El-Bastawissy EA; Abdelhady R; Younis NS; El-Hamamsy MH
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157411. PubMed ID: 36629449
[TBL] [Abstract][Full Text] [Related]
13. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
14. Identification of new IDH2
Chen X; Wu X; Gao J; Ying H; Dong X; Che J; Shen Z
Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000063. PubMed ID: 33184958
[TBL] [Abstract][Full Text] [Related]
15. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
[TBL] [Abstract][Full Text] [Related]
16. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2
Wei Q; Yao K; Yang J; Zhou Q; Liu P; Chen J; Liu H; Lai Y; Cao P
J Med Chem; 2023 Sep; 66(18):12894-12910. PubMed ID: 37706660
[TBL] [Abstract][Full Text] [Related]
17. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
Ma R; Yun CH
Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
[TBL] [Abstract][Full Text] [Related]
18. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2.
Wang F; Li Z; Zhang T; Yan G; Hu M; Zhao L; Zhao Y; Chen Y
Chem Biol Drug Des; 2018 Jun; 91(6):1087-1093. PubMed ID: 29120536
[TBL] [Abstract][Full Text] [Related]
20. A lymphoblast model for IDH2 gain-of-function activity in d-2-hydroxyglutaric aciduria type II: novel avenues for biochemical and therapeutic studies.
Kranendijk M; Salomons GS; Gibson KM; Van Schaftingen E; Jakobs C; Struys EA
Biochim Biophys Acta; 2011 Nov; 1812(11):1380-4. PubMed ID: 21889589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
